Harbin Yat Chau Pharmaceutical Products Co., Ltd.
-
Founded in:
1993-01-06 -
Country:
China -
Address:
No. 1, Xiangyun Road, Area A, Hanan Industrial New Town, Harbin Economic and Technological Development Zone -
Tax NO.:
91230199607173645K -
Registered Funds:
10 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Bupleurum |
|
0 | ||
| CURCUMAE RADIX |
|
0 | ||
| Gardenia (fried) |
|
0 | ||
| Arisaema cum bile |
|
0 | ||
| Poria |
|
0 | ||
| ACORI TATARINOWII RHIZOMA |
|
0 | ||
| Polygala tenuifolia (made) |
|
0 | ||
| Greenish lily bulb |
|
0 | ||
| Chinese date seeds (fried) |
|
0 | ||
| Nylon gear |
|
0 | ||
| FRUCTUS TRITICI LEVIS |
|
0 | ||
| Licorice (roasted) |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| COPTIDISRHIZOMA |
|
0 | ||
| Chrysophanic acid |
|
481-74-3 | 0 | |
| RADIX SCUTELLARIAE |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Bupleurum |
|
0 | ||
| Tian Jihuang |
|
0 | ||
| Artemisiae Scopariae Herba |
|
0 | ||
| Taraxasterol |
|
0 | ||
| DGL |
|
0 | ||
| LYSIMACHIAE HERBA |
|
0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.
More
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease. |
79902-63-9 | 63 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Simvastatin |
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease.
More
This product itself is inactive. After oral absorption, its hydrolysis product competitively inhibits the rate-limiting enzyme hydroxymethylglutaryl coenzyme A reductase in the cholesterol synthesis process in the body, reducing the synthesis of cholesterol and increasing the synthesis of low-density lipoprotein receptors. The main site of action is in the liver, resulting in lower blood cholesterol and low-density lipoprotein cholesterol levels, moderately lower serum triglyceride levels and increased blood high-density lipoprotein levels. This has an effect on the prevention and treatment of atherosclerosis and coronary heart disease. |
79902-63-9 | 63 |